If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is the formulation of Zepbound® (tirzepatide) the same in the single-dose pen and single-dose vial?
The tirzepatide single-dose pen and single-dose vial contain the identical active ingredient, tirzepatide. They also contain the same inactive ingredients.
See important safety information, including boxed warning, in the attached prescribing information.
Formulation of Approved Zepbound Presentations
Zepbound (tirzepatide) is approved by the Food and Drug Administration (FDA) in a
- single-dose pen, and
- single-dose vial.1
The single-dose pen and single-dose vial have the identical active ingredient, tirzepatide, and are designed to deliver the same doses.1
Regardless of presentation, tirzepatide is administered subcutaneously once weekly, and the dosing regimen and administration sites (abdomen, thigh or back of upper arm) remain the same.1
Attributes of the Tirzepatide Single-Dose Vial Versus Single-Dose Pen
The tirzepatide formulation provided in the single-dose vial is the same as in the single-dose pen that was tested in the SURMOUNT clinical trial program in adults with obesity or overweight or moderate-to-severe obstructive sleep apnea and obesity.1-6
This includes the same excipients, excipient concentrations, and drug substance concentration.7
The single-dose vial and single-dose pen contain 1 fixed dose and have a dosing volume of 0.5 mL per dose.1
Both the single-dose vial and single-dose pen are for single use and do not contain preservatives.1
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
2Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
3Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
4Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w
5Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
6Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. https://doi.org/10.1056/NEJMoa2404881
7Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: January 09, 2025